Author + information
- Sagar Mallikethi-Reddya,b,
- Naveen Trehana,b,
- Shanker Kundumadama,b,
- Tesfaye Telilaa,b,
- Anupama Kottama,b,
- Shaun Cardozoa,b,
- Melvyn Rubenfirea,b,
- Luis Afonsoa,b and
- Cindy Grinesa,b
Background: National trends in in-hospital outcomes and predictors of major adverse cardiac events (MACE) after transcatheter mitral valve replacement with MitraClip are not well studied.
Methods: We used ICD-9CM principal procedure code 35.97, in Healthcare Utilization Project, Nationwide inpatient Sample database (2010-2012) and identified 572 MitraClip procedures. Various in-hospital complications and trends of major adverse events were determined. SPSS Statistics 23 was used for the analysis.
Results: Mean age was 72 years. Nearly 38% were females. Hemorrhagic complications requiring blood transfusions were noted in 19.3%; acute kidney injury in 13.9%; pericardiocentesis was needed in 0.9%. MACE such as stroke or transient ischemic attack, myocardial infarction and in-hospital mortality were noted in 1.7%, 0.9% and 1.6% respectively. Overall rate of MACE was 4.2%. Rate of MACE was 0% in 2010; 2% in 2011 and 6.6% in 2012 (P-trend=0.008). Overall mean length of stay post-MitraClip implantation was 4.2 days. Mean hospitalization charges were $125,766. About 58% of patients were discharged home within 3 days post MitraClip implantation. Approximately 92% were discharged home and 7.4% were discharged to extended care facilities. Blood transfusions were significantly associated with higher risk for MACE (Adjusted OR: 20.1; 95%CI: 7.05-57.34; p<0.001).
Conclusions: MACE were noted in 4.2% of patients undergoing MitraClip implantation. There was a significant increase in MACE rate from 2010 through 2012 in the United States. Blood transfusions were associated with significantly higher risk for MACE.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM
Abstract Category: 24. Interventional Cardiology: Mitral and Structural Heart Disease
Presentation Number: 1156-179
- 2017 American College of Cardiology Foundation